Introduction
============

Familial hypercholesterolaemia is characterized by raised low-density lipoprotein cholesterol (LDL-C) and premature onset of cardiovascular disease. Without effective lipid-lowering treatment (LLT), adults with heterozygous familial hypercholesterolaemia (HeFH) have a very high risk of a coronary event by age 50. Statins can reduce this risk, but patients still have an approximately two-fold excess of coronary heart disease mortality vs. the general population.[@ehw388-B1]

Lipoprotein apheresis removes apoproteinB100-containing lipoproteins from the blood.[@ehw388-B2] It is generally regarded as a last-resort option for patients with progressive cardiovascular disease and persistently elevated LDL-C.[@ehw388-B2] Apheresis is expensive and can only be performed in specialized centres,[@ehw388-B3] the availability of which varies in different countries. As LDL-C concentrations quickly return to pre-treatment levels, patients must undergo a regular weekly or every 2 weeks (Q2W) apheresis regimen, depending on the patient's LDL-C value and local practice.[@ehw388-B4] Lipoprotein apheresis acutely lowers the LDL-C concentration by 50--75%, but the time-averaged reduction approximates 30%.

Alirocumab is a fully human monoclonal antibody that binds PCSK9 and inhibits PCSK9-mediated hepatic catabolism of the low-density lipoprotein receptor. Alirocumab as monotherapy or on a background of LLT reduced LDL-C by 44--58% in patients with and without HeFH.[@ehw388-B5] The 150 mg Q2W dose in combination with statin therapy with or without other LLT reduced LDL-C by 62--72%.[@ehw388-B10] These data showing robust decreases in LDL-C suggested that alirocumab may allow a reduction in the frequency of standard apheresis treatments (weekly or Q2W) or remove the need for apheresis in patients with HeFH. Therefore, the objective of this study was to evaluate the effect of alirocumab 150 mg Q2W vs. placebo on the standardized rate of apheresis treatments in patients with HeFH.

Methods
=======

ODYSSEY ESCAPE (<https://www.clinicaltrials.gov/ct2/show/>NCT023 26220) was a randomized, double-blind, placebo-controlled, parallel-group, phase 3 study in patients with HeFH undergoing regular weekly or Q2W lipoprotein apheresis. The study was conducted at 14 sites in the United States and Germany; screening started in March 2015 and was completed in September 2015.

The study design has been published.[@ehw388-B14] The main study criteria are detailed in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Table S1*. Eligible patients had HeFH (diagnosed by genotyping or clinical criteria[@ehw388-B15]^,^[@ehw388-B16]), had undergone consistent lipoprotein apheresis weekly for ≥4 weeks or Q2W for ≥8 weeks, and had maintained a stable background medical LLT, diet, and exercise level for ≥8 weeks. Patients undergoing all lipoprotein apheresis techniques were recruited (for additional information, see [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Text S1*).[@ehw388-B14] Patients with homozygous familial hypercholesterolaemia (FH) were excluded. Patients continued to take their background LLT and remained on a stable diet and exercise regimen from screening until the end of treatment visits.[@ehw388-B14]

The study was approved by the local institutional review boards, and was conducted according to the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and applicable local laws and regulations. All patients provided written informed consent.

Intervention
------------

During the 2-week screening period, patients provided informed consent, were checked for eligibility, and underwent a lipid panel and other laboratory testing, safety evaluation, and dietary review.[@ehw388-B14] LDL-C was calculated using the Friedewald formula (for information on laboratory analyses, as well as the well-being analysis, see [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Text S1*).[@ehw388-B17]

Qualifying patients were randomly assigned (2:1, respectively) to receive alirocumab 150 mg or placebo subcutaneously Q2W for 18 weeks during the double-blind treatment period. Randomization was done centrally using an interactive voice or web response system and a permuted-block design to ensure even distribution of treatment assignment. Randomization was stratified by frequency of apheresis procedure (weekly or Q2W) and normal (\<30 mg/dL) or elevated (≥30 mg/dL) lipoprotein (a) values. Treatment injections (in 1-mL volume) were administered at the site by research staff using an autoinjector, starting on the day of randomization. The drug or placebo was administered immediately after completion of the apheresis procedure on days when the two coincided.

The double-blind treatment period comprised two intervals: (phase 1) from day 1 to week 6, the apheresis rate was fixed according to the patient's established schedule (weekly or Q2W); (phase 2) from week 7 to week 18, the apheresis rate was adjusted based on the patient's LDL-C response to treatment, determined by blinded point-of-care testing. Apheresis was not performed when the LDL-C value at that visit was ≥30% lower than the baseline (pre-apheresis) LDL-C value, as described previously.[@ehw388-B14] Site personnel and patients were blinded to the LDL-C value and treatment assignment, and only received an alert as to whether apheresis should be performed on the basis of coded and blinded point-of-care LDL-C results.

Patients in Germany who completed the double-blind treatment period were offered an optional open-label extension (to week 86) (results for these patients are not currently available). The extension was not offered to patients in the United States because alirocumab is commercially available, but patients had the option to initiate clinical treatment with alirocumab or evolocumab. Patients who were not eligible or who chose not to enter the extension were followed for 8 weeks after the end of the double-blind treatment period, or after premature discontinuation of study treatment.

Outcome measures
----------------

The primary efficacy endpoint was the rate of apheresis treatments over 12 weeks (weeks 7 to 18), standardized according to the number of planned treatments for each individual patient. Key secondary endpoints are listed in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Table S2*.

Safety was assessed based on adverse event reports and laboratory analyses during the treatment-emergent adverse event (TEAE) period (defined as the time from the first dose of double-blind study treatment to the last injection plus 70 days \[10 weeks\], as alirocumab was anticipated to have a residual effect lasting for 10 weeks after the last injection).

Statistical analyses
--------------------

We estimated that a sample size of 63 patients (alirocumab 42: placebo 21) would have at least 85% power to detect a 33% difference in mean apheresis rates using a two-sided significance level and assuming a standard deviation (SD) of 40%.[@ehw388-B14]

The primary efficacy analysis population was the primary intent-to-treat (ITT) population, defined as all randomized patients. The secondary efficacy analysis population was based on randomized patients who had atleast one pre-apheresis calculated LDL-C value before the first dose of study drug (or randomization, if the patient did not receive any study drug) and at least one calculated LDL-C value in one of the pre-apheresis analysis windows up to week 6. The statistical analysis was conducted when the last patient completed all efficacy assessments at week 18. LDL-C data were analysed *posthoc* using the Kroon[@ehw388-B18] formula (see [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Text S1*) to estimate the interval means of LDL-C in weeks 6--18 (after potential withdrawal of apheresis therapy).

The standardized rate of apheresis treatments was analysed through the rate of treatments received during the 12-week period (week 7 to week 18), divided by the number of planned treatments (6 for Q2W and 12 for weekly), using the ranked analysis of covariance (ANCOVA) model.[@ehw388-B19] The standardized apheresis rate could range from 0 to 1, with 0 indicating that the patient skipped all planned apheresis treatments between week 7 to week 18, and 1 indicating that the patient received all planned treatments. A rate of 0.75 indicated that the patient received 75% of planned apheresis treatments (and skipped 25% of planned treatments). Patient drop-outs were accounted for as described in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Text S1*. The median treatment difference was determined using the Hodges--Lehmann estimation and 95% confidence intervals (CIs) using Moses distribution-free CI (see [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Text S1*).[@ehw388-B14]

We used a hierarchical inferential approach to control type I error. As the primary endpoint analysis was significant at the 5% alpha level, key secondary efficacy endpoints were tested sequentially (see [Supplementary material online, *Table S2*](#sup1){ref-type="supplementary-material"}).[@ehw388-B14]

Results
=======

Seventy-six patients with HeFH undergoing regular weekly or Q2W lipoprotein apheresis provided consent to participate and were screened; 62 (71.6%) patients were eligible for randomization in the study. Forty-one patients were randomly assigned to alirocumab and 21 to placebo (see [Supplementary material online, *Figure S1*](#sup1){ref-type="supplementary-material"}). All randomized patients received double-blind study treatment and were included in the safety population. Sixty patients completed the 6-week double-blind treatment period (40 \[97.6%\] in the alirocumab group and 20 \[95.2%\] in the placebo group) (i.e. when apheresis rate was determined by the patient's established schedule), and 57 completed the 18-week double-blind treatment period (37 \[90.2%\] and 20 \[95.2%\], respectively), when the apheresis schedule was determined by LDL-C value previously achieved. Of the five (8.1%) patients who prematurely discontinued study treatment, one (4.8%) was on placebo (withdrawn due to adverse events) and four (9.8%) were on alirocumab (two were withdrawn for adverse events and one for poor compliance, one patient withdrew consent).

The mean ± SD age of the population was 58.7 ± 9.7 years, 36 (58.1%) patients were men, and 60 (96.8%) were white. The median (minimum, maximum) duration of apheresis treatments before entry into the study was 4.9 (0.5, 32.9) years.

The baseline characteristics were balanced between treatment groups (*Table*[1](#ehw388-T1){ref-type="table"} and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Table S3*). The mean calculated baseline LDL-C (at study entry) was 4.5 ± 1.4 mmol/L (175.1 mg/dL) in the alirocumab group and 5.0 ± 1.8 mmol/L (191.6 mg/dL) in the placebo group (*P *=* *0.35). Twenty-seven (43.5%) patients followed a weekly apheresis schedule at baseline and 35 (56.5%) patients followed a Q2W schedule. The mean LDL-C value in patients undergoing weekly apheresis was 3.9 ± 1.3 mmol/L (151.3 ± 51.3 mg/dL) vs. 5.3 ± 1.4 mmol/L (204.9 ± 55.7 mg/dL) in patients undergoing Q2W apheresis. Thirty-eight (61.3%) patients had normal baseline lipoprotein (a) levels (\<30 mg/dL) and 24 (38.7%) had elevated levels. Thirty-four (54.8%) patients were taking a statin at screening, 19 (55.9%) of whom were on a maximum daily dose. Baseline LDL-C values were 4.0 ± 1.4 mmol/L (155.0 ± 54.6 mg/dL) among statin-treated patients compared with 5.4 ± 1.4 mmol/L (208.0 ± 53.2 mg/dL) in patients not taking a statin. Thirty patients (48.4%) were from Germany and 32 (51.6%) from the United States (see [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Table S4*). Table 1**Baseline characteristics  (randomized patients)**[^a^](#ehw388-TF2){ref-type="table-fn"}CharacteristicAlirocumab  (*n* = 41)Placebo  (*n* = 21)Age  (years), mean  ± SD59.5  ± 9.257.0  ± 10.5Men, *n*  (%)26  (63.4)10  (47.6)Race, *n*  (%)[^b^](#ehw388-TF3){ref-type="table-fn"} White39  (95.1)21  (100) Black or African American2  (4.9)0Body mass index  (kg/m^2^), mean  ± SD30.5  ± 5.030.3  ± 6.2Country, *n*  (%) Germany20  (48.8)10  (47.6) United States21  (51.2)11  (52.4)Previous PCI or CABG, *n*  (%)35  (85.4)14  (66.7)Time from hypercholesterolaemia diagnosis  (years), mean  ± SD13.3  ± 12.915.2  ± 14.0Frequency of apheresis, *n*  (%) Weekly18  (43.9)9  (42.9) Every 2 weeks23  (56.1)12  (57.1)Time from first known apheresis treatment  (years), median  (IQR)4.5  (0.5, 32.9)5.3  (0.5, 27.3)Background lipid-modifying therapy at randomization, *n*  (%) Any statin19  (46.3)13  (61.9) High-intensity statin[^c^](#ehw388-TF4){ref-type="table-fn"}13  (31.7)12  (57.1) Any LLT[^d^](#ehw388-TF5){ref-type="table-fn"} other than statins  (with or without statin)26  (63.4)16  (76.2)LDL-C at baseline, mean  ± SD or median  (IQR) (mmol/L) \[mg/dL\] LDL-C  (measured formula)4.5  ± 1.3  \[174.0  ± 51.4\]5.0  ± 1.7  \[195.0  ± 66.9\] Range1.4--6.8  \[56--265\]2.3--8.1  \[90--313\] Median  (IQR)4.6  (3.3:5.7)\[176.0  (129.0:219.0)\]4.7  (3.6:6.2)\[180.0  (140.0:240.0)\]LDL-C  (Friedewald formula)  (mmol/L)  \[mg/dL\]4.5  ± 1.4  \[175.1  ± 54.6\]5.0  ± 1.8  \[191.6  ± 68.9\] Range1.4--7.1  \[53--275\]2.1--8.2  \[81--316\][^2][^3][^4][^5][^6]

The mean ± SD duration of injection exposure was 17.4 ± 2.3 weeks (8.6 ± 1.3 injections) in the alirocumab group and 17.5 ± 3.1 weeks (8.4 ± 1.7 injections) in the placebo group.

Efficacy
--------

The primary efficacy endpoint achieved statistically significant benefit in favour of alirocumab-treated patients, with a Hodges--Lehmann median estimate of the treatment difference vs. placebo of 0.75 (95% CI 0.67--0.83). Therefore, alirocumab-treated patients had a 0.75 (75%) additional reduction in the standardized rate of apheresis treatments vs. placebo-treated patients (*P *\<* *0.0001) (*Table*[2](#ehw388-T2){ref-type="table"}). The median treatment difference in the standardized rate of apheresis treatments from week 7 to week 18, when apheresis treatment was determined by LDL-C concentration previously achieved, was 0.75 (95% CI 0.58--0.92) for patients who had been undergoing weekly apheresis and 0.67 (95% CI 0.50--1.00) for those on a Q2W schedule, in favour of alirocumab. Table 2Primary study endpoint and key secondary endpointAlirocumab (*n* = 41)Placebo  (*n* = 21)Alirocumab vs. placeboHodges--Lehmann estimate of median treatment difference (95% Moses distribution-free CI)*P* valuePrimary endpoint: Standardized rate of apheresis treatments over 12 weeks  (from weeks 7 to 18),[^a^](#ehw388-TF7){ref-type="table-fn"} median  (minimum, maximum), %0  (0, 100)83  (42, 100)0.75  (0.67--0.83)\<0.0001Key secondary endpoint: Standardized rate of apheresis treatments during week 15 to week 18,[^a^](#ehw388-TF7){ref-type="table-fn"} median  (minimum, maximum), %0  (0, 0)100  (50, 100)0.50  (0.50--1.00)\<0.0001[^7][^8]

The median treatment difference in the standardized rate of apheresis treatments over the 4-week period (week 15 to week 18) was 0.50 (95% CI 0.50 -- 1.00; *P *\<* *0.0001) in favour of alirocumab, indicating a 50% reduction in the standardized rate of apheresis treatments vs. placebo (*Table*[2](#ehw388-T2){ref-type="table"}). The individual patient reductions in apheresis over the 12-week period are illustrated in *Figure*[1A](#ehw388-F1){ref-type="fig"}. During this period, 63.4% of patients on alirocumab had no apheresis procedures, and 92.7% avoided at least half of the procedures (*Figure*[1B](#ehw388-F1){ref-type="fig"}). The rate of apheresis treatments according to apheresis schedule is illustrated in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Figure S2*. Figure 1(A) Individual patients' reductions in standardized rate of apheresis treatments from week 7 to week 18; (*B*) Standardized rate of apheresis treatments from week 7 to week 18 (intent-to-treat) by randomized treatment. Two patients (one in each randomized treatment group) terminated study treatments before week 6, and their standardized apheresis rates were imputed as 1 (i.e. 100%).

The mean pre-apheresis LDL-C value decreased from 4.5 mmol/L (175 mg/dL) at baseline to 2.3 mmol/L (90 mg/dL) at week 6 in the alirocumab group; corresponding data for patients in the placebo group are 5.0 mmol/L (192 mg/dL) and 4.8 mmol/L (185 mg/dL) (*Figure*[2](#ehw388-F2){ref-type="fig"}).

The least square (LS) mean ± standard error (SE) (95% CI) per cent change in pre-apheresis LDL-C from baseline at week 6 was Figure 2Pre-apheresis low-density lipoprotein cholesterol values (mean, with 95% CI) achieved at 2-weekly time-points (intent-to-treat analysis). The arrow indicates the time from which apheresis treatments could be avoided, when a ≥ 30% reduction in low-density lipoprotein cholesterol was achieved vs. baseline (pre-apheresis). Values above the lines indicate LS mean low-density lipoprotein cholesterol values. Values below week 6 and week 18 data points indicate LS mean (95% CI) per cent change from baseline. --53.7 ± 2.3 (--58.2 to --49.2) in the alirocumab group and 1.6 ± 3.1 (--4.7 to 7.9) in the placebo group (LS mean ± SE per cent difference --55.3 ± 3.9, 95% CI --63.1 to --47.5; *P *\<* *0.0001) (*Figure*[2](#ehw388-F2){ref-type="fig"} and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Table S5*). By week 18, the mean LDL-C value in the alirocumab group had risen slightly, to 2.9 mmol/L (110 mg/dL), compared with 4.9 mmol/L (191 mg/dL) in the placebo group (LS mean ± SE per cent difference --46.4 ± 7.9, 95% CI --62.3 to --30.5; *P *\<* *0.0001) (*Figure*[2](#ehw388-F2){ref-type="fig"} and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Table S5*). Results for other selected key secondary endpoints are shown in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Table S5*. Results from the well-being analysis are given in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Text S2* and *Table S6*.

A cross-validation, comparing point-of-care LDL-C values with central laboratory values, showed that both measures were highly correlated (Pearson's correlation 0.86) ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *Text S3*).

Per cent change from baseline to week 18 in lipoprotein (a) was --5.7% for alirocumab vs. --3.0% for placebo among patients with normal baseline values, and 4.9% vs. 7.6%, respectively, in patients with elevated baseline values ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *Table S7*). During weeks 7--18, when apheresis treatment could be withdrawn, alirocumab treatment was associated with a lower mean ± SD time-averaged LDL-C value (using the Kroon formula[@ehw388-B18]) over the course of the (potential) apheresis interval of 2.4 ± 1.3 mmol/L (92.7 ± 50.2 mg/dL) vs. 3.8 ± 1.7 mmol/L (146.7 ± 65.6 mg/dL) for placebo (*P *\<* *0.0001).

In a *posthoc* analysis, the time-averaged LDL-C values in the alirocumab-treated patients were consistently lower than those in the placebo-treated patients ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *Figure S3*).

Safety
------

TEAEs were reported by 75.6% of patients in the alirocumab group and by 76.2% of patients in the placebo group, none of which were fatal (*Table*[3](#ehw388-T3){ref-type="table"}). The rates of serious adverse events (9.8% for alirocumab and 9.5% for placebo) and events leading to treatment discontinuation (4.9% and 4.8%, respectively) were also similar in both groups. Table 3TEAEs[^a^](#ehw388-TF9){ref-type="table-fn"}**and laboratory parameters  (safety population) at 18 weeks**Alirocumab (*n* = 41)Placebo (*n* = 21)Any TEAE, *n*  (%)31  (75.6)16  (76.2)Treatment-emergent serious adverse event, *n*  (%)4  (9.8)2  (9.5)TEAE leading to death, *n*  (%)00TEAE leading to treatment discontinuation, *n*  (%)2  (4.9)1  (4.8)TEAEs by system organ class occurring in ≥ 2% of patients in either group, *n*  (%) General disorders and administration site conditions13  (31.7)4  (19.0) Musculoskeletal and connective tissue disorders13  (31.7)4  (19.0) Infections and infestations12  (29.3)8  (38.1) Gastrointestinal disorders10  (24.4)3  (14.3) Injury, poisoning and procedural complications8  (19.5)3  (14.3) Respiratory, thoracic and mediastinal disorders8  (19.5)2  (9.5) Nervous system disorders7  (17.1)1  (4.8) Laboratory investigations[^b^](#ehw388-TF10){ref-type="table-fn"}5  (12.2)3  (14.3) Cardiac disorders4  (9.8)3  (14.3) Skin and subcutaneous tissue disorders4  (9.8)1  (4.8) Blood and lymphatic system disorders2  (4.9)1  (4.8) Metabolism and nutrition disorders2  (4.9)1  (4.8) Psychiatric disorders2  (4.9)1  (4.8) Vascular disorders1  (2.4)2  (9.5) Immune system disorders1  (2.4)0 Ear and labyrinth disorders1  (2.4)0 Reproductive system and breast disorders1  (2.4)0 Eye disorders01  (4.8)TEAEs occurring in ≥ 5% of patients in either group or TEAEs of interest, *n*  (%) Fatigue6  (14.6)2  (9.5) Nasopharyngitis4  (9.8)2  (9.5) Diarrhoea4  (9.8)0 Myalgia4  (9.8)1  (4.8) Upper respiratory tract infection3  (7.3)4  (19.0) Headache3  (7.3)1  (4.8) Arthralgia3  (7.3)2  (9.5) Nausea2  (4.9)3  (14.3) Pruritus2  (4.9)1  (4.8) Back pain2  (4.9)2  (9.5) Injection site reaction1  (2.4)0 Palpitations02  (9.5)Laboratory parameters, *n*  (%) Alanine aminotransferase \> 3 × ULN00 Creatine kinase \> 3 × ULN3  (7.3)0[^9][^10][^11]

Three patients (7.3%) in the alirocumab group and none in the placebo group had two consecutive pre-apheresis calculated LDL-C values \<0.7 mmol/L (25 mg/dL). Two of these patients had at least one adverse event, one of which had several serious adverse events (pneumonia, acute myocardial infarction, acute respiratory failure, congestive heart failure, sepsis, and aortic valve stenosis). Twenty-seven patients (23 \[56.1%\] on alirocumab and 4 \[19.0%\] on placebo) had two consecutive LDL-C values \<0.7 mmol/L after apheresis, of which 15 (65.2%) and 2 (50.0%), respectively, had an adverse event. None of the events was serious but one patient (4.3%) discontinued treatment with alirocumab.

Discussion
==========

The ODYSSEY ESCAPE study was conducted in HeFH patients who had been undergoing regular lipoprotein apheresis. The study achieved the primary endpoint in the ITT population of a statistically significant 75% reduction in the standardized rate of apheresis in favour of alirocumab (*P *\<* *0.0001). The standardized rate of apheresis was at least halved in 39 of 41 (92.7%) patients on alirocumab, with 63.4% having no apheresis procedures during the 12-week period. Patients receiving alirocumab had lower time-averaged LDL-C values than placebo-treated patients.

At week 6, the pre-apheresis LDL-C concentration was reduced by 53.7% in patients on alirocumab, in line with the anticipated reduction. Consequently, the percentage of patients on apheresis at week 7 dropped markedly in the alirocumab group. Whereas 15 of the 21 placebo-treated patients avoided some of their planned apheresis treatments, three placebo-treated patients achieved a ≥50% reduction in the apheresis rate. The reasons for this reduction in the apheresis rate with placebo are unclear, but may reflect individual variation in LDL-C values, perhaps due to changes in diet or adherence to LLT, the small sample size, and the fact that patients were in a supervised clinical trial.

All of the patients in this study were at high cardiovascular risk and had taken LLT previously, including statins. At screening, only 54.8% of the patients were taking a statin, 55.9% of whom were on a maximally tolerated dose. A large proportion of the overall population reported a history of down-titration of statin treatment due to tolerability issues (43.5%) and 62.9% reported changing to a different statin. Various reasons were given for not taking a statin or for not taking it at the maximum daily dose, ranging from muscle symptoms to anxiety about side-effects, and regional practices/local labelling, indicating that patients with HeFH on apheresis present a diverse and difficult-to-treat population, with limited treatment options.

Patients in the USA showed different characteristics to those in Germany, with higher baseline LDL-C, greater prevalence of statin intolerance, and a less frequent apheresis regimen. In the USA, lipoprotein apheresis for HeFH is often only considered for patients who, after 6 months, do not have an adequate response to maximum tolerated drug therapy and have elevated LDL-C plus other cardiovascular risk factors.[@ehw388-B20] In Germany, where apheresis centres are more common, apheresis is considered within 12 months of failure of diet and LLT, and at a lower LDL-C threshold, and weekly is preferred to Q2W apheresis.[@ehw388-B20] Furthermore, recommendations for LDL-C lowering from Europe[@ehw388-B3] are based on a risk-stratified treat-to-target approach, whereas US guidelines[@ehw388-B21] advocate a dose-adapted approach. In view of the approach adopted in European guidelines,[@ehw388-B3] in which the target LDL-C value is \<1.8 mmol/L (70 mg/dL), German patients on alirocumab with LDL-C above this target value would still meet the criteria for apheresis. Consequently, LLT with alirocumab may prove complementary to lipoprotein apheresis in patients with very high LDL-C or who fail to meet the target LDL-C value.

A small observational study involving three patients with HeFH on long-term apheresis, who ceased apheresis treatment and received single injections of evolocumab 140 mg Q2W subcutaneously over 7 weeks, reported similar results.[@ehw388-B22]

Limitations
-----------

The present study was conducted in two countries, with patients showing markedly different baseline and treatment characteristics. In order to account for these differences, the target level was based on per cent reduction from baseline in LDL-C rather than on achievement of a specific goal (e.g. \<1.8 mmol/L\[70 mg/dL\]) for any given patient. Thus, in some cases apheresis was interrupted despite the fact that specific LDL-cholesterol goals were not achieved. Guideline-recommended threshold values may be achievable in individual patients through treatment with alirocumab alone or in combination with lipoprotein apheresis. Furthermore, the study is limited by a relatively small sample size and the short trial duration. However, there is no reason to believe that longer--term studies or larger sample sizes would provide different results.

Conclusions
===========

Lipoprotein apheresis was discontinued in 63.4% of patients on alirocumab who were previously undergoing regular apheresis every 1 or 2 weeks, and the standardized rate was reduced by at least 50% in an additional 29.3% of patients. PCSK9 inhibition maintained LDL-C at a significantly reduced plateau level as a function of antibody dose over time, whereas LDL-C levels following lipoprotein apheresis started to increase towards pre-procedure levels very rapidly regardless of the frequency of apheresis administration. This difference between PCSK9 inhibition and apheresis translates into a cumulative area under the curve LDL-C benefit in favour of alirocumab, and may be of clinical significance over the long term. Alirocumab was generally safe and well tolerated. The findings from this study suggest a role for alirocumab in the overall management of patients with HeFH undergoing regular lipoprotein apheresis therapy, with the potential to avoid apheresis treatments or delay the requirement for such treatments.
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[^1]: **See page 3596 for the editorial comment on this article (doi:10.1093/eurheartj/ehw497)**

[^2]: CABG, coronary artery bypass graft; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; LLT lipid-lowering therapy; PCI, percutaneous coronary intervention; SD, standard deviation.

[^3]: There were no clinically or statistically significant between-group differences.

[^4]: Self-reported.

[^5]: 40--80 mg/day atorvastatin or 20--40 mg/day rosuvastatin.

[^6]: Colesevelam hydrochloride, colestipol, ezetimibe, fish oil, nicotinic acid, omega 3 fatty acids or omega-3-acid ethyl ester.

[^7]: CI, confidence interval; Q2W, every 2 weeks.

[^8]: The standardized rate of apheresis treatments was analysed through the rate of treatments received during the 12-week period  (week 7 to week 18), divided by the number of planned treatments  (6 for Q2W and 12 for weekly). One patient on a Q2W schedule was misstratified at the time of randomization; on the basis of the ITT approach, the data for this patient were included in the weekly group.

[^9]: TEAE, treatment-emergent adverse event; ULN, upper limit of normal.

[^10]: TEAEs are adverse events that developed or worsened or became serious during the TEAE period.

[^11]: Alanine aminotransferase increased, liver function test abnormal, blood creatine phosphokinase increased.
